Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November
November 01 2023 - 7:30AM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that members of its senior management team will present at three
upcoming investor conferences in November.
Conference Details:
Event: Guggenheim Healthcare Talks 5th Annual
Inflammation, Neurology & Immunology (INI) Conference
Details: Presenting in a fireside chat format on Tuesday,
November 7, 2023, at 2:30 PM ET and hosting investor meetings in
New York, NY
Event: Piper Sandler 35th Annual Healthcare Conference
Details: Presenting in a fireside chat format on Wednesday,
November 29, 2023, at 1:30 PM ET and hosting investor meetings in
New York, NY
Event: Evercore ISI HealthCONx 6th Annual Conference
Details: Presenting in a fireside chat format on Thursday,
November 30, 2023, at 1:45 PM ET and hosting investor meetings in
Miami, FL
Live webcasts of the presentations will be available on the
“Events & Presentations” page within the Investors Relations
section of Longboard’s website at https://www.longboardpharma.com/.
The presentations will be archived on the website for at least 30
days following the events.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
observed impact on 5-HT2B and 5-HT2A receptor subtypes. LP352 is
currently in a Phase 1b/2a clinical trial, the PACIFIC Study,
evaluating participants ages 12 to 65 years old with a broad range
of Developmental and Epileptic Encephalopathies (DEEs), including
Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Enrollment
was completed in the summer of 2023, and topline data are expected
in January 2024. Longboard is also evaluating LP659, an oral,
centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1
and 5 modulator, which is in development for the potential
treatment of rare neuroinflammatory conditions. Longboard expects
to initiate dosing in a Phase 1 single-ascending dose (SAD)
clinical trial for LP659 in healthy volunteers later this year.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. In
some cases, you can identify forward-looking statements by words
such as “will”, “upcoming”, “focus”, “working to”, “designed to”,
“expect”, “January 2024”, “later this year”, or the negative,
plural or other tenses of these words or other comparable language,
and they may include, without limitation, statements about the
following: Longboard’s participation in the upcoming conferences;
Longboard’s clinical and preclinical product candidates and
programs, including their advancement, timing of initiating dosing
in clinical trials, timing of topline data from clinical trials,
characteristics of clinical trial participants, their potential
(including to be highly selective and the numbers and types of
conditions they may address), and their design and characteristics;
Longboard’s ability to develop product candidates and deliver
medicines, and Longboard’s focus and work. For such statements,
Longboard claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Longboard’s expectations. Factors that could cause
actual results to differ materially from those stated or implied by
Longboard’s forward-looking statements include, but are not limited
to, the following: risks related to Longboard’s limited operating
history, financial position and need for additional capital;
Longboard will need additional managerial and financial resources
to advance all of its programs, and you and others may not agree
with the manner Longboard allocates its resources; risks related to
the development and commercialization of Longboard’s product
candidates; Longboard’s product candidates are in the early phases
of a lengthy research and development process, the timing, manner
and outcome of research, development and regulatory review is
uncertain, and Longboard’s product candidates may not advance in
research or development or be approved for marketing; enrolling
participants in Longboard’s ongoing and intended clinical trials is
competitive and challenging; PACIFIC Study participants’ diagnoses
are as of time of screening and are subject to change;
macroeconomic events stemming from the COVID-19 pandemic or
evolving geopolitical developments such as the conflicts in Ukraine
and the Middle East, including but not limited to the impact on
Longboard’s clinical trials and operations, the operations of
Longboard’s suppliers, partners, collaborators, and licensees, and
capital markets, which in each case remains uncertain; risks
related to unexpected or unfavorable new data; nonclinical and
clinical data is voluminous and detailed, and regulatory agencies
may interpret or weigh the importance of data differently and reach
different conclusions than Longboard or others, request additional
information, have additional recommendations or change their
guidance or requirements before or after approval; results of
clinical trials and other studies are subject to different
interpretations and may not be predictive of future results;
topline data may not accurately reflect the complete results of a
particular study or trial; risks related to relying on licenses or
collaborative arrangements; other risks related to Longboard’s
dependence on third parties; competition; product liability or
other litigation or disagreements with others; government and
third-party payor actions, including relating to reimbursement and
pricing; risks related to regulatory compliance; and risks related
to Longboard’s and third parties’ intellectual property rights.
Additional factors that could cause actual results to differ
materially from those stated or implied by Longboard’s
forward-looking statements are disclosed in Longboard’s filings
with the Securities and Exchange Commission (SEC). These
forward-looking statements represent Longboard’s judgment as of the
time of this release. Longboard disclaims any intent or obligation
to update these forward-looking statements, other than as may be
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101003298/en/
Megan E. Knight Head of Investor Relations
IR@longboardpharma.com 858.789.9283
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024